Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers Meeting Abstract
| Authors: | Jhaveri, K.; Han, H.; Dotan, E.; Oh, D. Y.; Ferrario, C.; Tolcher, A.; Lee, K. W.; Liao, C. Y.; Kang, Y. K.; Kim, Y. H.; Hamilton, E.; Spira, A.; Patel, N.; Karapetis, C.; Rha, S. Y.; Boyken, L.; Woolery, J.; Bedard, P. |
| Abstract Title: | Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S749 |
| End Page: | S750 |
| Language: | English |
| ACCESSION: | WOS:000866211600454 |
| DOI: | 10.1016/j.annonc.2022.07.589 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 460MO -- Source: Wos |
